Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2019

View Archived Issues

Huntington's and astrocytes: no good guys, bad guys

Novel wogonin derivatives as potent and selective CDK9 inhibitors for leukemia treatment

Preclinical studies of gelonin-chlorotoxin fusion protein for targeted glioblastoma therapy

Viral m6A methylation upregulates RSV replication and pathogenesis, emerging as a potential target

Tricyclic resveratrol boosts blood stem cell transduction rates

[211At]Farletuzumab shows efficacy in a disseminated ovarian cancer mouse model

[68Ga]JMV-6659 shows promising for PET imaging of tumors expressing NTS1

KNG as a potential new biomarker during epileptogenesis

PD-340 alleviates behavioral deficits related to cognitive impairment in mouse model of AD

VBJ-192 and VBJ-215 show encouraging results without tolerance or locomotor side effects

Novel gamma-secretase inhibitor PIPE-505 restores synaptic function, regenerates outer hair cells

Cantabio Pharmaceuticals forms collaboration for drugs targeting DJ-1 protein

Mochida Pharmaceutical divulges muscarinic M3 receptor PAMs

Bicycle Therapeutics, Oxford Drug Discovery Institute to work on therapeutics for dementia

Blade Therapeutics identifies new calpain inhibitors

Hanlim Pharmaceutical presents new cathepsin K inhibitors

Grant supports clinical trial of personalized treatment approach for aplastic anemia

Response to treatment observed in phase Ib/II trial of onvansertib in KRAS-mutated colorectal cancer

Takeda Pharmaceutical patents ionotropic glutamate GluN2B receptor antagonists

BUGWORKS Research India synthesizes new antibacterials

Provention reports phase IIa topline results for PRV-6527 in moderate to severe Crohn's disease

Vast Therapeutics' BIOC-11 eradicates 99% of NTM in animal model

Washington University to study effects of Kaleido's Microbiome Metabolic Therapies

CheckMate-9LA study of Opdivo plus low-dose Yervoy in first-line NSCLC meets primary endpoint

Talaris begins phase III trial of FCR-001 in living donor kidney transplant recipients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...